TABLE 1.
Clinicopathologic features of patients with idiopathic inflammatory myopathies
| Patients with idiopathic inflammatory myopathies (n = 489) | |||
|---|---|---|---|
| Anti‐NT5C1A positive | Anti‐NT5C1A negative | P | |
| Number of patients | 206 (42) | 283 (58) | |
| Sex (M:F) | 105:101 | 139:144 | 0.71 |
| Age at onset, mean (SD), years | 57.8 (10.1) | 55.5 (14.8) | 0.05 |
| Maximum CK level, median, IU/L | 451 | 479 | <0.01 |
| Dysphagia, no. (%) | 89/199 (45) | 71/255 (28) | <0.01 |
| Antinuclear antibody, no. (%) | 43/73 (59) | 28/152 (18) | <0.01 |
| Other antibodies 1 , no. (%) | 49/138 (36) | 113/250 (45) | 0.07 |
| Muscle biopsy findings, no. (%) | |||
| Perimysial inflammation | 59/152 (39) | 84/233 (36) | 0.59 |
| MHC‐class1 upregulation | 102/117 (87) | 139/199 (70) | <0.01 |
CK, creatine kinase; MHC, major histocompatibility complex.
1
Antibodies against MDA5, TIF1γ, NXP2, Mi2, Jo‐1, EJ, OJ, HMGCR, SRP, SS‐A, SS‐B, PM‐Scl, and U1snRNP were included. The P‐values less than 0.05 are marked in bold.